You are here: Home » Opinion » Letters
Business Standard

Letter to BS: Hope Oxford Covid-19 vaccine put an end to our misery

There is something to rejoice as Serum Institute of India has entered into a manufacturing partnership with AstraZeneca once the vaccine trial is successful

Coronavirus Vaccine | Coronavirus

Business Standard 

covid-19, vaccine, coronavirus

The good news that early-stage clinical trials of the Oxford University Covid-19 vaccine candidate (AZD1222), licensed by AstraZeneca pharmaceuticals, is safe and in­duces an immune response truly gives the world a glimmer of hope at a time when it is facing one of the deadliest pandemic in recent times. Though more tests have to be done before it is made available for public, there is hope for mankind even as the pandemic has already claimed more than six lakh lives and infected millions of people around the globe. Many other nations, including India, are also on the path of developing a vaccine.



What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.


Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, July 23 2020. 00:51 IST